Microfluidic Lymphoid Tissue-on-Chip for Immune Response Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models of human lymph nodes fail to accurately mimic the three-dimensional organization and immune responses of human lymphoid tissue, leading to discrepancies between animal and human immunological studies, particularly in the development and testing of immunotherapies.
Innovation Solution
A microfluidic device that mimics human lymphoid tissue using an organ-on-chip technology, featuring a matrix with B and T lymphocytes, an extracellular matrix, and perfusion channels to replicate the lymph node's architecture and immune responses, allowing for the study of immune reactions to various stimuli and therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If 2D culture of PBMCs is used, then the assay is simple and quick, but the three-dimensional organization and cellular phenotype are lost, failing to mimic human lymph node tissue
Solution Approach 1:
The patent transitions from two-dimensional PBMC culture to three-dimensional lymph node tissue reconstruction using microfluidic chambers. The device creates a 3D extracellular matrix environment that recapitulates the structural organization of human lymph nodes, enabling accurate modeling of cellular phenotypes and tissue architecture that cannot be achieved in 2D culture.
Solution Approach 2:
The microfluidic device creates an in vitro model that copies the essential architectural features and cellular organization of human lymph nodes. By reconstructing the 3D tissue structure with appropriate cell types and extracellular matrix, the device provides a faithful replica of lymph node biology for studying immune responses and immunotherapy effects.
2Reliability
If animal models (mouse homologs or humanized mice) are used, then the studies can be conducted in vivo, but the immune responses do not correspond to human studies due to genetic engineering requirements and tissue disruption
Solution Approach 1:
The patent replaces complex in vivo animal models with an in vitro microfluidic tissue model. This substitution eliminates the need for genetic engineering, cytokine treatment, and surgery while maintaining the ability to study human immune responses. The microfluidic device provides a controlled environment that accurately reflects human lymph node biology without the complications of animal models.
3Quantity of substance
If humanized mice are used to study human immune tissue, then human immune cells can be studied, but survival is poor and immune responses are impaired due to graft versus host disease and tissue disruption
Solution Approach 1:
The microfluidic device creates an in vitro model that copies the essential architectural features and cellular organization of human lymph nodes. By reconstructing the 3D tissue structure with appropriate cell types and extracellular matrix, the device provides a faithful replica of lymph node biology for studying immune responses and immunotherapy effects.
4Shape
If existing 3D lymph node models (HuALN, MIMIC) are used, then some three-dimensional structure is achieved, but the T and B lymphocytes are disorganized or the immune response does not mature
Solution Approach 1:
The microfluidic device segments the lymph node into distinct functional zones with specific cell types and structures. This segmentation allows for the organized arrangement of T and B lymphocytes, dendritic cells, and stromal cells in their respective compartments, achieving the level of organization found in native lymph nodes.
Solution Approach 2:
The device implements local quality by creating different microenvironments within the lymph node model, each with specific cell types, extracellular matrix composition, and structural features. This local differentiation recapitulates the heterogeneous architecture of human lymph nodes, enabling accurate study of localized immune responses.
Data Source
AI summary
An organ-on-a-chip microfluidic device is disclosed that mimics a human lymph node and/or human lymphoid tissue. The device can include cells from human blood and lymphatic tissue, include an extracellular matrix for the development of immune system components, and provide for the perfusion of fluids and solids resembling blood and lymphatic fluid within micrometer sized channels.